董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anthony DiGiandomenico | 男 | Independent Director | 59 | 未披露 | 416.24 | 2026-03-30 |
| Christopher A. Marlett | 男 | Chairman of the Board | 60 | 未披露 | 416.24 | 2026-03-30 |
| James U. Bowie | 男 | Independent Director | 65 | 未披露 | 60.39 | 2026-03-30 |
| James J. Lalonde | 男 | Independent Director | 65 | 10.19万美元 | 3.29 | 2026-03-30 |
| Edgardo Rayo | 男 | Independent Director | 39 | 未披露 | 7.79 | 2026-03-30 |
| Lon E. Bell | 男 | Independent Director | 85 | 10.19万美元 | 2.51 | 2026-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Heltzen | 男 | Chief Executive Officer and President | 45 | 106.04万美元 | 25.71 | 2026-03-30 |
| Fouad Nawaz | 男 | Vice President, Finance | 40 | 35.17万美元 | 4.45 | 2026-03-30 |
| Tyler Korman | 男 | Chief Scientific Officer | 47 | 31.48万美元 | 80.36 | 2026-03-30 |
| Paul Opgenorth | 男 | Vice President, Development | 44 | 31.06万美元 | 未持股 | 2026-03-30 |
| Damien Perriman | 男 | Chief Commercial Officer | 49 | 31.08万美元 | 8.69 | 2026-03-30 |
董事简历
中英对照 | 中文 | 英文- Anthony DiGiandomenico
-
Anthony DiGiandomenico，自公司于2021年8月10日成立以来，他一直担任New Venture Discovery的负责人和董事。2013年7月至今，他还担任增强超声技术开发商ENDRA Life Sciences Inc.（纳斯达克股票代码：NDRA）的董事会成员；2017年1月至2020年5月，担任多种药物治疗开发商Provention Bio， Inc.的董事会成员；从2016年1月至2019年10月，开发用于选择性调节人类免疫系统的新型生物药物，以治疗广泛的癌症和自身免疫性疾病。自1997年共同创立前身为MDB Capital Group， LLC的Public Ventures以来，DiGiandomenico先生一直致力于对早期颠覆性技术的投资。他曾与生物技术、医疗设备、高科技和可再生能源领域的众多公司合作。他持有加州大学伯克利分校哈斯商学院的工商管理硕士学位和Colorado大学的金融学士学位。
Anthony DiGiandomenico joined Endra Life Sciences Inc.'s Board of Directors in 2013. A co founder of MDB Capital Group LLC, Mr. DiGiandomenico focuses on corporate finance and capital formation for growth oriented companies. He has participated in all areas of corporate finance including private capital, public offerings, PIPEs, business consulting and strategic planning, and mergers and acquisitions.Mr. DiGiandomenico has also worked on a wide range of transactions for growth oriented companies in biotechnology, nutritional supplements, manufacturing and entertainment industries. Prior to forming MDB Capital Group LLC in 1997, Mr. DiGiandomenico served as President and CEO of the Digian Company, a real estate development company. Mr. DiGiandomenico has also served on the board of directors of Cue Biopharma, Inc., an immunotherapy company, and on the board of directors of Provention Bio, Inc., a clinical stage biopharmaceutical company.Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a BS in Finance from the University of Colorado. - Anthony DiGiandomenico，自公司于2021年8月10日成立以来，他一直担任New Venture Discovery的负责人和董事。2013年7月至今，他还担任增强超声技术开发商ENDRA Life Sciences Inc.（纳斯达克股票代码：NDRA）的董事会成员；2017年1月至2020年5月，担任多种药物治疗开发商Provention Bio， Inc.的董事会成员；从2016年1月至2019年10月，开发用于选择性调节人类免疫系统的新型生物药物，以治疗广泛的癌症和自身免疫性疾病。自1997年共同创立前身为MDB Capital Group， LLC的Public Ventures以来，DiGiandomenico先生一直致力于对早期颠覆性技术的投资。他曾与生物技术、医疗设备、高科技和可再生能源领域的众多公司合作。他持有加州大学伯克利分校哈斯商学院的工商管理硕士学位和Colorado大学的金融学士学位。
- Anthony DiGiandomenico joined Endra Life Sciences Inc.'s Board of Directors in 2013. A co founder of MDB Capital Group LLC, Mr. DiGiandomenico focuses on corporate finance and capital formation for growth oriented companies. He has participated in all areas of corporate finance including private capital, public offerings, PIPEs, business consulting and strategic planning, and mergers and acquisitions.Mr. DiGiandomenico has also worked on a wide range of transactions for growth oriented companies in biotechnology, nutritional supplements, manufacturing and entertainment industries. Prior to forming MDB Capital Group LLC in 1997, Mr. DiGiandomenico served as President and CEO of the Digian Company, a real estate development company. Mr. DiGiandomenico has also served on the board of directors of Cue Biopharma, Inc., an immunotherapy company, and on the board of directors of Provention Bio, Inc., a clinical stage biopharmaceutical company.Mr. DiGiandomenico holds an MBA from the Haas School of Business at the University of California, Berkeley and a BS in Finance from the University of Colorado.
- Christopher A. Marlett
-
Christopher A. Marlett，自2019年4月成立以来一直担任公司董事。Marlett先生自2021年8月10日成立以来一直担任MDB资本控股有限责任公司的首席执行官兼董事会主席和董事。Marlett先生自1997年以来一直担任Public Ventures（前身为MDBCapital Group，LLC）的首席执行官和联合创始人。在证券行业工作的36年里，他主导了多笔风险阶段上市公司的融资，并致力于优化这一方法，以推出有前景的技术/业务平台。对于MDB已上市的所有公司，他在共同创立和制定商业化和融资战略方面起到了不可或缺的作用。此外，他还在早期阶段担任过几家上市公司的董事会成员。他在尼加拉瓜开发人力资本发展平台方面投入了大量精力，该平台已导致创建了该国最大的呼叫中心园区，雇用了大约3,000名员工，并开展了几项知识流程外包业务，以支持MDB的业务。他开发了尼加拉瓜第一家专利服务公司，该公司被出售给了伦敦证交所上市的专利律师和服务平台Murgitroyd。他是PatentVest的联合创始人，从2003年开始开发该平台。他拥有南加州大学工商管理理学学士学位。Marlett先生的领导能力和财务经验使他能够很好地担任Invizyne Technologies Inc.董事会成员。
Christopher A. Marlett has served as a director of the Company since its inception in April 2019. Mr. Marlett has been the chief executive officer and chairman of the board of directors and a director of MDB Capital Holdings, LLC since inception on August 10, 2021.The Company appointed Mr. Marlett as Chairman of the board on February 17, 2025. Mr. Marlett has been since 1997, the Chief Executive Officer and a co founder of MDB Capital (formerly known as MDB Capital Group, LLC). Over his 36 years of working in the securities industry, he has led multiple financings for venture stage public companies and has dedicated his efforts to optimizing this method to launch promising technology/business platforms. He has been integral in co founding and developing the commercialization and financing strategy for all the companies MDB has taken public. In addition, he has served as a board member of several of the public companies in the early stages. He has invested significant efforts in developing a human capital development platform in Nicaragua that has led to the creation of the largest call center park in the country employing approximately 3,000 people and several knowledge process outsourcing operations to support MDB's businesses. He developed the first patent services company in Nicaragua that was sold to Murgitroyd an LSE listed patent attorney and services platform. He is the co founder of PatentVest and developed the platform from inception in 2003. He holds a Bachelor of Science degree in Business Administration from the University of Southern California. Mr. Marlett's leadership and extensive corporate and financial experience position him well to serve as a member of Exozymes Inc.'s board of directors. - Christopher A. Marlett，自2019年4月成立以来一直担任公司董事。Marlett先生自2021年8月10日成立以来一直担任MDB资本控股有限责任公司的首席执行官兼董事会主席和董事。Marlett先生自1997年以来一直担任Public Ventures（前身为MDBCapital Group，LLC）的首席执行官和联合创始人。在证券行业工作的36年里，他主导了多笔风险阶段上市公司的融资，并致力于优化这一方法，以推出有前景的技术/业务平台。对于MDB已上市的所有公司，他在共同创立和制定商业化和融资战略方面起到了不可或缺的作用。此外，他还在早期阶段担任过几家上市公司的董事会成员。他在尼加拉瓜开发人力资本发展平台方面投入了大量精力，该平台已导致创建了该国最大的呼叫中心园区，雇用了大约3,000名员工，并开展了几项知识流程外包业务，以支持MDB的业务。他开发了尼加拉瓜第一家专利服务公司，该公司被出售给了伦敦证交所上市的专利律师和服务平台Murgitroyd。他是PatentVest的联合创始人，从2003年开始开发该平台。他拥有南加州大学工商管理理学学士学位。Marlett先生的领导能力和财务经验使他能够很好地担任Invizyne Technologies Inc.董事会成员。
- Christopher A. Marlett has served as a director of the Company since its inception in April 2019. Mr. Marlett has been the chief executive officer and chairman of the board of directors and a director of MDB Capital Holdings, LLC since inception on August 10, 2021.The Company appointed Mr. Marlett as Chairman of the board on February 17, 2025. Mr. Marlett has been since 1997, the Chief Executive Officer and a co founder of MDB Capital (formerly known as MDB Capital Group, LLC). Over his 36 years of working in the securities industry, he has led multiple financings for venture stage public companies and has dedicated his efforts to optimizing this method to launch promising technology/business platforms. He has been integral in co founding and developing the commercialization and financing strategy for all the companies MDB has taken public. In addition, he has served as a board member of several of the public companies in the early stages. He has invested significant efforts in developing a human capital development platform in Nicaragua that has led to the creation of the largest call center park in the country employing approximately 3,000 people and several knowledge process outsourcing operations to support MDB's businesses. He developed the first patent services company in Nicaragua that was sold to Murgitroyd an LSE listed patent attorney and services platform. He is the co founder of PatentVest and developed the platform from inception in 2003. He holds a Bachelor of Science degree in Business Administration from the University of Southern California. Mr. Marlett's leadership and extensive corporate and financial experience position him well to serve as a member of Exozymes Inc.'s board of directors.
- James U. Bowie
-
James U. Bowie，自2019年4月成立以来一直担任公司董事。Bowie博士自1993年以来一直在加州大学洛杉矶分校化学和生物化学系任教，并于2002年至2019年6月担任UCLA-DOE研究所副主任，并于2012年至2019年6月担任副主席。他于2021年6月成为名誉教授。Bowie博士曾在四家学术期刊的编委会任职，组织了许多国际会议，并在众多国家和国际科学委员会任职，包括在2013年至2015年期间担任蛋白质学会主席。鲍伊博士于1981年在卡尔顿学院以优异成绩获得化学学士学位，1989年在麻省理工学院获得生物化学博士学位，并于1989年至1993年在加州大学洛杉矶分校从事博士后工作。他的作品被引用超过29,000次，并获得多个奖项的认可，包括被任命为生物物理学会院士和美国科学促进会院士。在整个职业生涯中，鲍伊博士的工作都集中在与蛋白质和酶结构相关的问题上。拥有药物筛选技术、蛋白质结构预测方法、酶系统设计等专利。Bowie博士对Invizyne基础酶技术的深入了解将对Invizyne Technologies Inc.董事会非常有价值。
James U. Bowie has served as an independent director of the Company since its inception in April 2019. Dr. Bowie has been on the faculty in the Department of Chemistry and Biochemistry at the University of California, Los Angeles since 1993 and served as Associate Director of the UCLA DOE Institute from 2002 to June 2019 and Vice Chair from 2012 through June 2019. He became Professor Emeritus in June 2021. Dr. Bowie served on the Editorial Boards of four academic journals, organized many international meetings and served on numerous national and international scientific committees, including service as President of the Protein Society from 2013 to 2015. Dr. Bowie obtained a B.A. with Distinction in Chemistry from Carleton College in 1981, a Ph.D. in Biochemistry from the Massachusetts Institute of Technology in 1989 and did postdoctoral work at the University of California, Los Angeles from 1989 to 1993. His work has been cited over 29,000 times and has been recognized with many awards, including being named Fellow of the Biophysical Society and Fellow of the American Association for the Advancement of Science. Throughout his career, Dr. Bowie's work has focused on issues related to protein and enzyme structure. He holds patents on drug screening technology, methods for protein structure prediction, and enzyme system design. - James U. Bowie，自2019年4月成立以来一直担任公司董事。Bowie博士自1993年以来一直在加州大学洛杉矶分校化学和生物化学系任教，并于2002年至2019年6月担任UCLA-DOE研究所副主任，并于2012年至2019年6月担任副主席。他于2021年6月成为名誉教授。Bowie博士曾在四家学术期刊的编委会任职，组织了许多国际会议，并在众多国家和国际科学委员会任职，包括在2013年至2015年期间担任蛋白质学会主席。鲍伊博士于1981年在卡尔顿学院以优异成绩获得化学学士学位，1989年在麻省理工学院获得生物化学博士学位，并于1989年至1993年在加州大学洛杉矶分校从事博士后工作。他的作品被引用超过29,000次，并获得多个奖项的认可，包括被任命为生物物理学会院士和美国科学促进会院士。在整个职业生涯中，鲍伊博士的工作都集中在与蛋白质和酶结构相关的问题上。拥有药物筛选技术、蛋白质结构预测方法、酶系统设计等专利。Bowie博士对Invizyne基础酶技术的深入了解将对Invizyne Technologies Inc.董事会非常有价值。
- James U. Bowie has served as an independent director of the Company since its inception in April 2019. Dr. Bowie has been on the faculty in the Department of Chemistry and Biochemistry at the University of California, Los Angeles since 1993 and served as Associate Director of the UCLA DOE Institute from 2002 to June 2019 and Vice Chair from 2012 through June 2019. He became Professor Emeritus in June 2021. Dr. Bowie served on the Editorial Boards of four academic journals, organized many international meetings and served on numerous national and international scientific committees, including service as President of the Protein Society from 2013 to 2015. Dr. Bowie obtained a B.A. with Distinction in Chemistry from Carleton College in 1981, a Ph.D. in Biochemistry from the Massachusetts Institute of Technology in 1989 and did postdoctoral work at the University of California, Los Angeles from 1989 to 1993. His work has been cited over 29,000 times and has been recognized with many awards, including being named Fellow of the Biophysical Society and Fellow of the American Association for the Advancement of Science. Throughout his career, Dr. Bowie's work has focused on issues related to protein and enzyme structure. He holds patents on drug screening technology, methods for protein structure prediction, and enzyme system design.
- James J. Lalonde
-
James J. Lalonde，自2024年4月1日起担任公司独立董事。Lalonde博士是合成生物学领域公认的领导者，并担任多家私营初创企业的科学顾问。自2023年8月以来，他一直担任Willow Biosciences Inc.的董事会主席。他曾于2019年9月至2021年8月在基因组工程技术的全球领导者Inscripta Inc.担任微生物数字基因组工程业务负责人，担任其微生物数字基因组工程业务的负责人。在此之前，2004年至2019年，Lalonde博士在蛋白质工程领域的领导者Codexis, Inc.担任研发高级副总裁。在Codexis工作的近15年里，他监督了50多种酶的开发，用于药物制造、营养、生物治疗和分子诊断。他还领导了该公司开创性的CodeEvolver的开发被授权给各大制药公司的蛋白质工程技术。在加入Codexis之前，Lalonde博士于1993年至2004年在Altus Biologics担任生物催化和化学开发方面的领导职务，并于1989年至1993年在Vista化学公司担任科学研究方面的领导职务。他拥有湖头大学化学学士学位（1983年）和得克萨斯农工大学有机化学博士学位（1987年）。他曾两次获得美国总统绿色化学奖，并于2022年入选德州农工大学杰出校友学院。
James J. Lalonde has served as an independent director of the Company since April 1, 2024. Dr. Lalonde is a recognized leader in the field of synthetic biology and serves as a Scientific Advisor for several private start up enterprises. He was Chairman of the Board of Willow Biosciences, Inc. from 2023 until the sale of the operating subsidiary to Mycofeast in 2025. He previously served as Lead, Microbial Digital Genome Engineering Business with Inscripta Inc. from September 2019 to August 2021, a global leader in genome engineering technology, as Lead of its Microbial Digital Genome Engineering Business. Prior to that, from 2004 to 2019 Dr. Lalonde was Senior Vice President of R&D at Codexis, Inc., a leader in protein engineering. In his nearly 15 years at Codexis he oversaw the development of more than 50 enzymes for drug manufacturing, nutrition, biotherapeutics, and molecular diagnostics. He also led the development of the company's pioneering CodeEvolver protein engineering technology which was licensed to major pharmaceutical companies. Prior to Codexis, Dr. Lalonde held leadership roles in biocatalysis and chemical development at Altus Biologics from 1993 to 2004 and in scientific research from 1989 to 1993 at Vista Chemical Company. He holds a bachelor's degree in chemistry from Lakehead University (1983) and a Ph.D. in organic chemistry from Texas A&M University (1987). He was a recipient of the US Presidential Green Chemistry Awards twice and was elected to the Academy of Distinguished Alumni at Texas A&M in 2022. - James J. Lalonde，自2024年4月1日起担任公司独立董事。Lalonde博士是合成生物学领域公认的领导者，并担任多家私营初创企业的科学顾问。自2023年8月以来，他一直担任Willow Biosciences Inc.的董事会主席。他曾于2019年9月至2021年8月在基因组工程技术的全球领导者Inscripta Inc.担任微生物数字基因组工程业务负责人，担任其微生物数字基因组工程业务的负责人。在此之前，2004年至2019年，Lalonde博士在蛋白质工程领域的领导者Codexis, Inc.担任研发高级副总裁。在Codexis工作的近15年里，他监督了50多种酶的开发，用于药物制造、营养、生物治疗和分子诊断。他还领导了该公司开创性的CodeEvolver的开发被授权给各大制药公司的蛋白质工程技术。在加入Codexis之前，Lalonde博士于1993年至2004年在Altus Biologics担任生物催化和化学开发方面的领导职务，并于1989年至1993年在Vista化学公司担任科学研究方面的领导职务。他拥有湖头大学化学学士学位（1983年）和得克萨斯农工大学有机化学博士学位（1987年）。他曾两次获得美国总统绿色化学奖，并于2022年入选德州农工大学杰出校友学院。
- James J. Lalonde has served as an independent director of the Company since April 1, 2024. Dr. Lalonde is a recognized leader in the field of synthetic biology and serves as a Scientific Advisor for several private start up enterprises. He was Chairman of the Board of Willow Biosciences, Inc. from 2023 until the sale of the operating subsidiary to Mycofeast in 2025. He previously served as Lead, Microbial Digital Genome Engineering Business with Inscripta Inc. from September 2019 to August 2021, a global leader in genome engineering technology, as Lead of its Microbial Digital Genome Engineering Business. Prior to that, from 2004 to 2019 Dr. Lalonde was Senior Vice President of R&D at Codexis, Inc., a leader in protein engineering. In his nearly 15 years at Codexis he oversaw the development of more than 50 enzymes for drug manufacturing, nutrition, biotherapeutics, and molecular diagnostics. He also led the development of the company's pioneering CodeEvolver protein engineering technology which was licensed to major pharmaceutical companies. Prior to Codexis, Dr. Lalonde held leadership roles in biocatalysis and chemical development at Altus Biologics from 1993 to 2004 and in scientific research from 1989 to 1993 at Vista Chemical Company. He holds a bachelor's degree in chemistry from Lakehead University (1983) and a Ph.D. in organic chemistry from Texas A&M University (1987). He was a recipient of the US Presidential Green Chemistry Awards twice and was elected to the Academy of Distinguished Alumni at Texas A&M in 2022.
- Edgardo Rayo
-
Edgardo Rayo，自2013年起受雇于MDB Capital，S.A.，该公司是MDB资本控股有限责任公司的关联公司。Rayo先生还是MDB资本的注册代表，该公司是一家注册经纪兼交易商，隶属于MDB资本控股有限责任公司。Rayo先生，于MDB Capital，S.A.，目前担任投资分析总监。在担任这一职务时，Rayo先生领导MDB资本在MDB资本的投资分析工作，提供战略见解，为投资决策提供依据，并帮助推动MDB资本的融资计划。在担任这一职务期间，他与生物技术、医疗设备和可再生能源等多个领域的公司进行了合作。在加入MDB资本之前，Rayo先生曾受雇于商业银行Banpro，在那里他管理着一个固定收益证券投资组合。Rayo先生获得了Ave Maria大学拉丁美洲校区金融和经济学专业的工商管理学士学位，并且是CFA特许持有人。
Edgardo Rayo has been employed by MDB Capital, S.A, since 2013, which is an affiliated company of MDB Capital Holdings, LLC. Mr. Rayo also is a registered representative of MDB Capital, a registered broker dealer, subsidiary of MDB Capital Holdings, LLC. Mr. Rayo, at MDB Capital, S.A., currently serves as the Director of Investment Analysis. In this role, Mr. Rayo leads the MDB Capital's investment analysis efforts at MDB Capital, providing strategic insights that inform investment decisions and helping to drive MDB Capital's capital raising initiatives. Under this role, he has collaborated with a diverse array of companies across sectors such as biotechnology, medical devices, and renewable energy. Prior to joining MDB Capital, Mr. Rayo was employed at Banpro, a commercial bank, where he managed a portfolio of fixed income securities. Mr. Rayo earned a bachelor's degree in business administration with a concentration in Finance and Economics from the Latin American campus of Ave Maria University and is a CFA Charterholder. - Edgardo Rayo，自2013年起受雇于MDB Capital，S.A.，该公司是MDB资本控股有限责任公司的关联公司。Rayo先生还是MDB资本的注册代表，该公司是一家注册经纪兼交易商，隶属于MDB资本控股有限责任公司。Rayo先生，于MDB Capital，S.A.，目前担任投资分析总监。在担任这一职务时，Rayo先生领导MDB资本在MDB资本的投资分析工作，提供战略见解，为投资决策提供依据，并帮助推动MDB资本的融资计划。在担任这一职务期间，他与生物技术、医疗设备和可再生能源等多个领域的公司进行了合作。在加入MDB资本之前，Rayo先生曾受雇于商业银行Banpro，在那里他管理着一个固定收益证券投资组合。Rayo先生获得了Ave Maria大学拉丁美洲校区金融和经济学专业的工商管理学士学位，并且是CFA特许持有人。
- Edgardo Rayo has been employed by MDB Capital, S.A, since 2013, which is an affiliated company of MDB Capital Holdings, LLC. Mr. Rayo also is a registered representative of MDB Capital, a registered broker dealer, subsidiary of MDB Capital Holdings, LLC. Mr. Rayo, at MDB Capital, S.A., currently serves as the Director of Investment Analysis. In this role, Mr. Rayo leads the MDB Capital's investment analysis efforts at MDB Capital, providing strategic insights that inform investment decisions and helping to drive MDB Capital's capital raising initiatives. Under this role, he has collaborated with a diverse array of companies across sectors such as biotechnology, medical devices, and renewable energy. Prior to joining MDB Capital, Mr. Rayo was employed at Banpro, a commercial bank, where he managed a portfolio of fixed income securities. Mr. Rayo earned a bachelor's degree in business administration with a concentration in Finance and Economics from the Latin American campus of Ave Maria University and is a CFA Charterholder.
- Lon E. Bell
-
Lon E. Bell，自2024年4月1日起生效。Bell博士作为独立董事会成员加入公司董事会。Bell博士于2021年创立了DTP Thermoelectrics LLC，并担任其首席执行官。该公司专注于商业化新一代固态加热、冷却和温度控制系统。Bell博士于2013年至2016年担任董事会成员，自2017年起担任CDTi Advanced Materials，Inc.的董事长，该公司是一家上市公司（CDTI：Pink Sheet）。Bell博士帮助指导CDTI通过一个支点，成为一家新兴的化学重整行业催化涂层系统开发商，服务于新兴的氢经济和碳氢化合物封存行业。自2008年起，Bell博士担任加州理工学院机械与土木工程系顾问委员会成员，并于2015年至2022年担任主席。Dr Bell此前值得注意的经历包括在1991年创立Amerigon（现为Gentherm Incorporated，NASDAQ：THRM），该公司已成为汽车行业固态热管理系统的主要供应商。此前，他于1968年创立了Technar，Incorporated，是汽车行业汽车碰撞传感器的先驱供应商。他指导公司从成立到1991年出售给TRW。在他的整个职业生涯中，Bell博士的发明获得了超过100项专利。他的五项发明集群已进入批量生产，并在其目标市场取得了可观的份额。Bell博士拥有加州理工学院数学学士学位（1962年）、火箭推进硕士学位（1963年）、机械工程博士学位（1968年）。
Lon E. Bell,joined the Board of Directors of the Company as an independent board member. Dr. Bell founded DTP Thermoelectrics LLC in 2021 and serves as its CEO. The company is focused on commercializing a new generation of solid-state heating, cooling and temperature control systems. Dr. Bell served as a board member from 2013 to 2016 and since 2017 has served as Chairman of CDTi Advanced Materials, Inc., a publicly traded company (CDTI: Pink Sheet). Dr Bell helped guide CDTI through a pivot to become an emerging developer of catalytic coating systems for the chemical reforming industry serving the emerging hydrogen economy and hydrocarbon sequestering industries. Since 2008 Dr. Bell has served as a member of the advisory board for the California Institute of Technology's Department of Mechanical and Civil Engineering, serving as the Chair from 2015 to 2022. Dr Bell's notable prior experiences include the founding of Amerigon (now Gentherm Incorporated, NASDAQ: THRM) in 1991, which has become a major supplier of solid-state thermal management systems to the automotive industry. Previously he founded Technar, Incorporated, in 1968, a pioneering supplier of automotive crash sensors to the automobile industry. He guided the company from its inception to its sale to TRW in 1991. Throughout his career, Dr. Bell has been granted over 100 patents for his inventions. Five clusters of his inventions have gone into mass production and achieved a significant share of their target markets. Dr. Bell has a bachelor's degree in mathematics (1962), master's degree in rocket propulsion (1963), and PhD in mechanical engineering (1968), from the California Institute of Technology. - Lon E. Bell，自2024年4月1日起生效。Bell博士作为独立董事会成员加入公司董事会。Bell博士于2021年创立了DTP Thermoelectrics LLC，并担任其首席执行官。该公司专注于商业化新一代固态加热、冷却和温度控制系统。Bell博士于2013年至2016年担任董事会成员，自2017年起担任CDTi Advanced Materials，Inc.的董事长，该公司是一家上市公司（CDTI：Pink Sheet）。Bell博士帮助指导CDTI通过一个支点，成为一家新兴的化学重整行业催化涂层系统开发商，服务于新兴的氢经济和碳氢化合物封存行业。自2008年起，Bell博士担任加州理工学院机械与土木工程系顾问委员会成员，并于2015年至2022年担任主席。Dr Bell此前值得注意的经历包括在1991年创立Amerigon（现为Gentherm Incorporated，NASDAQ：THRM），该公司已成为汽车行业固态热管理系统的主要供应商。此前，他于1968年创立了Technar，Incorporated，是汽车行业汽车碰撞传感器的先驱供应商。他指导公司从成立到1991年出售给TRW。在他的整个职业生涯中，Bell博士的发明获得了超过100项专利。他的五项发明集群已进入批量生产，并在其目标市场取得了可观的份额。Bell博士拥有加州理工学院数学学士学位（1962年）、火箭推进硕士学位（1963年）、机械工程博士学位（1968年）。
- Lon E. Bell,joined the Board of Directors of the Company as an independent board member. Dr. Bell founded DTP Thermoelectrics LLC in 2021 and serves as its CEO. The company is focused on commercializing a new generation of solid-state heating, cooling and temperature control systems. Dr. Bell served as a board member from 2013 to 2016 and since 2017 has served as Chairman of CDTi Advanced Materials, Inc., a publicly traded company (CDTI: Pink Sheet). Dr Bell helped guide CDTI through a pivot to become an emerging developer of catalytic coating systems for the chemical reforming industry serving the emerging hydrogen economy and hydrocarbon sequestering industries. Since 2008 Dr. Bell has served as a member of the advisory board for the California Institute of Technology's Department of Mechanical and Civil Engineering, serving as the Chair from 2015 to 2022. Dr Bell's notable prior experiences include the founding of Amerigon (now Gentherm Incorporated, NASDAQ: THRM) in 1991, which has become a major supplier of solid-state thermal management systems to the automotive industry. Previously he founded Technar, Incorporated, in 1968, a pioneering supplier of automotive crash sensors to the automobile industry. He guided the company from its inception to its sale to TRW in 1991. Throughout his career, Dr. Bell has been granted over 100 patents for his inventions. Five clusters of his inventions have gone into mass production and achieved a significant share of their target markets. Dr. Bell has a bachelor's degree in mathematics (1962), master's degree in rocket propulsion (1963), and PhD in mechanical engineering (1968), from the California Institute of Technology.
高管简历
中英对照 | 中文 | 英文- Michael Heltzen
Michael Heltzen，自2024年2月1日起担任公司首席执行官，此前于2023年10月至2024年1月担任公司首席战略官。在加入公司之前，Heltzen先生于2023年5月至2023年10月在Paragraf Ltd.担任战略执行副总裁一职。2019年1月至2023年5月，Heltzen先生担任Cardea Bio Inc.的首席执行官。在Nanosens Innovations Inc.与Cardea Bio Inc.合并之前，Heltzen先生还于2018年12月至2019年9月担任该公司的首席执行官和董事长。Heltzen先生还自2015年起担任EXO Incubator Inc的董事会主席，自2010年起担任Blue SEQ Innovations Inc.的董事会主席。
Michael Heltzen has served as the Chief Executive Officer of the Company since February 1, 2024 and previously served as the Chief Strategy Officer of the Company from October 2023 to January 2024.Mr. Heltzen was appointed to position of President on February 17, 2025. Prior to joining the Company, Mr. Heltzen held the position of Executive Vice President for Strategy at Paragraf Ltd. from May 2023 to October 2023. From January 2019 to May 2023 Mr. Heltzen served as the Chief Executive Officer of Cardea Bio Inc. Mr. Heltzen also served as the Chief Executive Officer and Chairman of Nanosens Innovations Inc., prior to its merger with Cardea Bio Inc., from December 2018 to September 2019. Mr. Heltzen has also served as the Chairman of the Board for EXO Incubator Inc. since 2015 and Chairman of the Board for Blue SEQ Innovations Inc. since 2010.- Michael Heltzen，自2024年2月1日起担任公司首席执行官，此前于2023年10月至2024年1月担任公司首席战略官。在加入公司之前，Heltzen先生于2023年5月至2023年10月在Paragraf Ltd.担任战略执行副总裁一职。2019年1月至2023年5月，Heltzen先生担任Cardea Bio Inc.的首席执行官。在Nanosens Innovations Inc.与Cardea Bio Inc.合并之前，Heltzen先生还于2018年12月至2019年9月担任该公司的首席执行官和董事长。Heltzen先生还自2015年起担任EXO Incubator Inc的董事会主席，自2010年起担任Blue SEQ Innovations Inc.的董事会主席。
- Michael Heltzen has served as the Chief Executive Officer of the Company since February 1, 2024 and previously served as the Chief Strategy Officer of the Company from October 2023 to January 2024.Mr. Heltzen was appointed to position of President on February 17, 2025. Prior to joining the Company, Mr. Heltzen held the position of Executive Vice President for Strategy at Paragraf Ltd. from May 2023 to October 2023. From January 2019 to May 2023 Mr. Heltzen served as the Chief Executive Officer of Cardea Bio Inc. Mr. Heltzen also served as the Chief Executive Officer and Chairman of Nanosens Innovations Inc., prior to its merger with Cardea Bio Inc., from December 2018 to September 2019. Mr. Heltzen has also served as the Chairman of the Board for EXO Incubator Inc. since 2015 and Chairman of the Board for Blue SEQ Innovations Inc. since 2010.
- Fouad Nawaz
Fouad Nawaz，自2023年9月起担任公司财务副总裁。在加入公司之前，Nawaz先生于2018年6月至2023年9月担任Fulham Co Inc.的财务副总裁。Nawaz先生于2007年在长滩加州州立大学获得工商管理理学学士学位。
Fouad Nawaz has served as the Vice President Finance of the Company since September 2023. Prior to joining the Company, Mr. Nawaz served as the Vice President of Finance at Fulham Co Inc. from June 2018 to September 2023. Mr. Nawaz received his Bachelor of Science degree in 2007 in Business Administration from California State University, Long Beach.- Fouad Nawaz，自2023年9月起担任公司财务副总裁。在加入公司之前，Nawaz先生于2018年6月至2023年9月担任Fulham Co Inc.的财务副总裁。Nawaz先生于2007年在长滩加州州立大学获得工商管理理学学士学位。
- Fouad Nawaz has served as the Vice President Finance of the Company since September 2023. Prior to joining the Company, Mr. Nawaz served as the Vice President of Finance at Fulham Co Inc. from June 2018 to September 2023. Mr. Nawaz received his Bachelor of Science degree in 2007 in Business Administration from California State University, Long Beach.
- Tyler Korman
Tyler Korman，自2024年2月1日起担任研究副总裁，此前曾于2019年8月至2024年1月担任公司研发总监。2014年6月至2019年9月，Korman博士是加州大学洛杉矶分校化学和生物化学系的项目科学家。Korman博士于2008年获得加州大学欧文分校分子生物学和生物化学博士学位，2003年获得理学硕士学位，2001年获得加州大学圣地亚哥分校化学理学学士学位。
Tyler Korman has served as Chief Scientific Officer effective as of November 2025 and previously served as Vice President, Research of the Company from February 2025 to October 2025. From June 2014 to September 2019 Dr. Korman was a Project Scientist in the Department of Chemistry and Biochemistry at the University of California, Los Angeles. Dr. Korman received his PhD in Molecular Biology and Biochemistry from the University of California, Irvine in 2008, Master of Science in 2003 and Bachelor of Science in 2001 in Chemistry from the University of California, San Diego.- Tyler Korman，自2024年2月1日起担任研究副总裁，此前曾于2019年8月至2024年1月担任公司研发总监。2014年6月至2019年9月，Korman博士是加州大学洛杉矶分校化学和生物化学系的项目科学家。Korman博士于2008年获得加州大学欧文分校分子生物学和生物化学博士学位，2003年获得理学硕士学位，2001年获得加州大学圣地亚哥分校化学理学学士学位。
- Tyler Korman has served as Chief Scientific Officer effective as of November 2025 and previously served as Vice President, Research of the Company from February 2025 to October 2025. From June 2014 to September 2019 Dr. Korman was a Project Scientist in the Department of Chemistry and Biochemistry at the University of California, Los Angeles. Dr. Korman received his PhD in Molecular Biology and Biochemistry from the University of California, Irvine in 2008, Master of Science in 2003 and Bachelor of Science in 2001 in Chemistry from the University of California, San Diego.
- Paul Opgenorth
Paul Opgenorth，自2024年2月1日起担任开发副总裁，此前曾于2019年8月至2024年1月担任公司研发总监。2017年5月至2019年8月，Opgenorth博士是劳伦斯伯克利国家实验室联合生物能源研究所的博士后科学家。Opgenorth博士于2015年在美国加州大学洛杉矶分校获得化学、生物化学和结构生物学博士学位，并于2004年在美国加州大学戴维斯分校获得化学理学学士学位。
Paul Opgenorth has served as Vice President of Development effective as of February 1, 2024 and previously served as Director of Research and Development of the Company from August 2019 to January 2024. From May 2017 to August 2019 Dr. Opgenorth was a postdoctoral scientist in the Joint BioEnergy Institute at Lawrence Berkeley National Lab. Dr. Opgenorth received his PhD in Chemistry, Biochemistry, and Structural Biology from the University of California, Los Angeles in 2015, and Bachelor of Science in 2004 in Chemistry from the University of California, Davis.- Paul Opgenorth，自2024年2月1日起担任开发副总裁，此前曾于2019年8月至2024年1月担任公司研发总监。2017年5月至2019年8月，Opgenorth博士是劳伦斯伯克利国家实验室联合生物能源研究所的博士后科学家。Opgenorth博士于2015年在美国加州大学洛杉矶分校获得化学、生物化学和结构生物学博士学位，并于2004年在美国加州大学戴维斯分校获得化学理学学士学位。
- Paul Opgenorth has served as Vice President of Development effective as of February 1, 2024 and previously served as Director of Research and Development of the Company from August 2019 to January 2024. From May 2017 to August 2019 Dr. Opgenorth was a postdoctoral scientist in the Joint BioEnergy Institute at Lawrence Berkeley National Lab. Dr. Opgenorth received his PhD in Chemistry, Biochemistry, and Structural Biology from the University of California, Los Angeles in 2015, and Bachelor of Science in 2004 in Chemistry from the University of California, Davis.
- Damien Perriman
Damien Perriman自2025年4月起担任公司首席商务官。在加入公司之前，Perriman先生曾在Gevo担任首席业务发展官，并于2010年至2024年在Genomatica担任特种产品高级副总裁。他较早的经验包括在Verdezyne担任业务发展领导职务、在陶氏化学公司担任技术商业化职位，以及担任昆士兰政府美洲贸易办事处的副贸易专员。Perriman先生还担任Cellugy董事会主席，为可再生材料和工业生物技术领域的几家早期公司提供建议。他拥有理学学士学位。（荣誉）新南威尔士大学工业化学博士，加州大学洛杉矶分校安德森管理学院MBA。
Damien Perriman has served as Chief Commercial Officer of the Company since April 2025. Prior to joining the Company, Mr. Perriman served as Chief Business Development Officer at Gevo and as Senior Vice President, Specialty Products at Genomatica from 2010 to 2024. His earlier experience includes business development leadership roles at Verdezyne, technology commercialization positions with The Dow Chemical Company, and service as a Deputy Trade Commissioner for the Queensland Government Trade Office for the Americas. Mr. Perriman also serves as Chairman of the Board of Cellugy and advises several early stage companies in the renewable materials and industrial biotechnology sectors. He holds a B.Sc. (Hons.) in Industrial Chemistry from the University of New South Wales and an MBA from the UCLA Anderson School of Management.- Damien Perriman自2025年4月起担任公司首席商务官。在加入公司之前，Perriman先生曾在Gevo担任首席业务发展官，并于2010年至2024年在Genomatica担任特种产品高级副总裁。他较早的经验包括在Verdezyne担任业务发展领导职务、在陶氏化学公司担任技术商业化职位，以及担任昆士兰政府美洲贸易办事处的副贸易专员。Perriman先生还担任Cellugy董事会主席，为可再生材料和工业生物技术领域的几家早期公司提供建议。他拥有理学学士学位。（荣誉）新南威尔士大学工业化学博士，加州大学洛杉矶分校安德森管理学院MBA。
- Damien Perriman has served as Chief Commercial Officer of the Company since April 2025. Prior to joining the Company, Mr. Perriman served as Chief Business Development Officer at Gevo and as Senior Vice President, Specialty Products at Genomatica from 2010 to 2024. His earlier experience includes business development leadership roles at Verdezyne, technology commercialization positions with The Dow Chemical Company, and service as a Deputy Trade Commissioner for the Queensland Government Trade Office for the Americas. Mr. Perriman also serves as Chairman of the Board of Cellugy and advises several early stage companies in the renewable materials and industrial biotechnology sectors. He holds a B.Sc. (Hons.) in Industrial Chemistry from the University of New South Wales and an MBA from the UCLA Anderson School of Management.